常规小剂量阿托伐他汀对急性冠脉综合征患者超C反应蛋白影响的观察被引量：1

The observation of the effect of conventional low-dose atorvastatin on acute coronary syndrome patients with hs-CRP

在线阅读下载PDF

导出

摘要目的探讨常规小剂量阿托伐他汀对急性冠脉综合征(ACS)患者血清超C反应蛋白(hs-CRP)的影响及意义。方法将80例ACS患者随机分2组:常规治疗组(对照组),阿托伐他汀治疗组(观察组)。分别采用免疫比浊法测定hs-CRP测定这2组患者治疗前,治疗后4周,患者血清中hs-CRP的变化。结果观察组治疗4周后hs-CRP与治疗前相比差异有统计学意义(P<0.05)。结论常规小剂量阿托伐他汀治疗,可以显著降低血浆中炎症反应标志物hs-CRP的浓度,具有可观的治疗价值。 Objective To investigate the effect and the significance of conventional low-dose atorvastatin on acute coronary syndrome （ ACS） in patients with hs-CRP. Methods 80 cases of ACS patients were randomly divided into conventional therapy group （ control group） ,atorvastatin treatment guoup （ observation group）. To measure changes of hs-CRP before treatment,4 weeks after treatment,by using immunotur bidimetric assay. Results 4 weeks after treatment,hs-CRP of the observation group compared with the pre-treatment differences were significont （ P 0. 05）. Conclusion By the conventional low-dose atorvastatin therapy,can significantly reduce the plasma concentrations of hs-CRP,has considerationable therapeutic value.

作者徐林徐懿

机构地区山东省泰安市第四人民医院

出处《中国实用医药》 2010年第23期49-50,共2页 China Practical Medicine

关键词急性冠脉综合征超敏C反应蛋白阿托伐他汀 Acute coronary syndrome High-sensitivity C-reactive protein Atorvastatin

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1马焕云,崔忠生.冠心病患者心血管事件的危险性与hs-CRP的关系研究新进展[J].中国医师进修杂志（内科版）,2007,30(8):68-69. 被引量：9
2吴惠玲,何国祥,刘建平,冉擘力,李永华,仝识非,姚青,唐波.血浆超敏C反应蛋白水平与冠心病及粥样斑块的关系[J].临床心血管病杂志,2006,22(7):405-407. 被引量：30
3Hong MK,Mintz GS.Comparison of coronary plaque rupture between stable angina and acute my cardial infarction:a threevessel Intravascular ultrasound study in 235 patients.Circulation,2004,110:928-933.

二级参考文献19

1葛智平,陈晓春.C反应蛋白与不同类型冠心病相关性的临床研究[J].临床心血管病杂志,2005,21(2):78-80. 被引量：37
2石文蕾,张煜,张维,宫玲,王慧婷,朱毅,郑柏生,殷民德.超敏C反应蛋白与老年冠心病严重程度的关系[J].国外医学（心血管疾病分册）,2005,32(3):182-184. 被引量：17
3黄玮,陈庆伟,雷寒,邓玮,柯大智.纤维蛋白原与高敏C反应蛋白对稳定性冠心病患者心血管事件的预测价值[J].中华心血管病杂志,2006,34(8):718-721. 被引量：34
4WU M H, WANG J H, LAI C P, et al. Association of hs-CRP with the severity of coronary artery diasease and myocardial infarction[J]. Int J Cardiol,2004, 97(Suppl 2): S47-47.
5TANIGUCHI H, MOMIYAMA Y, OHMORI R, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease[J]. Atherosclerosis, 2005, 178: 173-177.
6TAKANO M, INAMI S, ISHIBASHI F, et al. Angioscopic follow-up study of coronary ruptured plaques in nonculprit lesions [J]. J Am Coll Cardiol, 2005,45: 652-658.
7Devaraj S,Kumaresan PR,Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol, 2004, 36(3) :405-410.
8Wang CH,Li SH,Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation, 2003,107(13) : 1783-1790.
9Blann AD, Lip GY. Effects of C-reactive protein on the release of yon Willebrand factor,E-selectin,thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis, 2003,14 (4) : 335-340.
10Verma S, Kuliszewski MA, Li SH, et al.C-reactive protein attenuates endothelial progenitor cell survival,differentiation ,and function :further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation, 2004,109(17) : 2058-2067.